Table 5. Independent association of CRP, fibrinogen and their interaction with disease control or progression at re-evaluation.
| Variables | Re-evaluation | Univariate | Multivariate, adjusted | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease control | Progression | OR | 95% CI | OR | 95% CI | P | |||
| CRP | 13.8 (5.1–51.6) | 30.0 (11.6–60) | 1.00 | 0.99–1.01 | 0.92 | 0.85–0.99 | 0.026 | ||
| Fibrinogen | 5.3 (4.0–7.0) | 5.6 (4.9–6.7) | 0.91 | 0.71–1.16 | 0.60 | 0.36–1.00 | 0.051 | ||
| Interaction CRP fibrinogen | 1.00 | 1.00–1.00 | 1.01 | 1.00–1.02 | 0.019 | ||||
| Age | 64 [57–70] | 62 [54–69] | 1.03 | 0.99–1.08 | 1.04 | 0.98–1.10 | 0.242 | ||
| Sex, n (%) | |||||||||
| Male | 61 (58.1) | 44 (41.9) | 1 | 1 | |||||
| Female | 23 (63.9) | 13 (36.1) | 1.28 | 0.58–2.79 | 3.56 | 0.74–17.28 | 0.115 | ||
| Histological type | |||||||||
| Squamous cell carcinoma | 33 (61.1) | 21 (38.9) | 1 | 1 | |||||
| Adenocarcinoma | 36 (60.0) | 24 (40.0) | 0.96 | 0.45–2.03 | 0.69 | 0.21–2.34 | 0.554 | ||
| NSCLS-NOS | 13 (52.0) | 12 (48.0) | 0.69 | 0.27–1.79 | 0.71 | 0.14–3.69 | 0.680 | ||
| Chemotherapy protocol | |||||||||
| GP | 21 (58.3) | 15 (41.7) | 1 | 1 | |||||
| PE | 20 (58.8) | 14 (41.2) | 1.02 | 0.39–2.64 | 1.43 | 0.25–8.35 | 0.688 | ||
| PC | 31 (60.8) | 20 (39.2) | 1.11 | 0.46–2.64 | 1.11 | 0.21–5.83 | 0.898 | ||
| Other | 12 (60.0) | 8 (40.0) | 1.07 | 0.35–3.26 | 0.97 | 0.16–6.02 | 0.974 | ||
| Antibiotic | |||||||||
| No | 75 (60.5) | 49 (39.5) | 1 | 1 | |||||
| Yes | 6 (54.5) | 5 (45.5) | 0.78 | 0.23–2.71 | 0.61 | 0.11–3.39 | 0.568 | ||
Data are presented as median (interquartile range). CRP, C reactive protein; OR, odds ratio; 95% CI, 95% confidence interval.